CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 94 enrolled
Drug / intervention
Drug: Apixaban sprinkle capsules +1 moredrug
Likely dose
Drug: Apixaban sprinkle capsules 0.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03509883
NCT03509883Phase 1Completed
CompareCT.gov

A Study to Assess the Absorption of Apixaban (BMS-562247) Sprinkle Capsules Compared With Tablets in Healthy Volunteers

Bristol-Myers Squibb·interventional·Posted Apr 26, 2018·Updated Jan 23, 2020

In Brief

A Phase 1 clinical trial evaluating Drug: Apixaban sprinkle capsules and Experimental: Apixaban tablets followed by apixaban sprinkle capsules for Healthy Volunteers. Completed, enrolled 94 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the absorption of apixaban (BMS-562247) into the bloodstream of healthy volunteers, when administered as sprinkle capsules compared to tablets. Eligible participants will be randomly assigned to 1 of 2 treatment sequences and will receive a single oral dose of apixaban twice during the course of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 26, 2018
Enrollment StartApr 26, 2018
Primary CompletionJun 15, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.2 years ago

Interventions

Drug: Apixaban sprinkle capsulesdrug

Single dose (25 x 0.1 mg capsules), oral administration

Experimental: Apixaban tablets followed by apixaban sprinkle capsulesdrug

Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration